Birgitta Versluijs

37 Pulmonary complications of childhood cancer treatment and guidelines for management. Am J Pediatr Hematol Oncol 1985;7:71–8. 20. Sleijfer S. Bleomycin-induced pneumo- nitis. Chest 2001;120:617–24. 21. Mathes DD. Bleomycin and hyperoxia exposure in the operating room. Anesth Analg 1995;81:624–9. 22. Liles A, Blatt J, Morris D, et al. Monito- ring pulmonary complications in long- term childhood cancer survivors: gui- delines for the primary care physician. Cleve Clin J Med 2008;75:531–9. 23. De A, Guryev I, LaRiviere A, et al. Pul- monary function abnormalities in childhood cancer survivors treated with bleomycin. Pediatr Blood Cancer 2014;61:1679–84. 24. Aakre BM, Efem RI, Wilson GA, Kor DJ, Eisenach JH. Postoperative acute res- piratory distress syndrome in patients with previous exposure to bleomycin. Mayo Clin Proc 2014;89:181–9. 25. de Wit R, Sleijfer S, Kaye SB, et al. Bleo- mycin and scuba diving: where is the harm? Lancet Oncol 2007;8:954–5. 26. Bruno B, Souillet G, Bertrand Y, Werck- Gallois MC, So Satta A, Bellon G. Effects of allogeneic bone marrow transplanta- tion on pulmonary function in 80 child- ren in a single paediatric centre. Bone Marrow Transplant 2004;34:143–7. 27. Marras TK, Chan CK, Lipton JH, Mes- sner HA, Szalai JP, Laupacis A. Long- term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Trans- plant 2004;33:509–17. 28. Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004;25: 53–64. 29. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Resp Crit Care Med 1996; 154:1851–6. 30. Segura A, Yuste A, Cercos A, et al. Pulmonary fibrosis induced by cycl- ophosphamide. Ann Ppharmacother 2001;35:894–7. 31. Weiss RB, Poster DS, Penta JS. The ni- trosoureas and pulmonary toxicity. Can- cer Treat Rev 1981;8:111–25. 32. O’Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA. Late carmustine lung fibrosis. Age at treatment may influence severity and survival. Chest 1995; 107:1355–7. 33. Denbo JW, Zhu L, Srivastava D, et al. Long-term pulmonary function after metastasectomy for childhood osteo- sarcoma: a report from the St Jude lifetime cohort study. J Am Coll Surg 2014;219:265–71. 34. Gower WA, Collaco JM, Mogayzel Jr PJ. Pulmonary dysfunction in pediatric hematopoietic stem cell transplant pa- tients: non-infectious and long-term complications. Pediatr Blood Cancer 2007;49:225–33. 35. Panoskaltsis-Mortari A, Griese M, Mad- tes DK, et al. An official American Tho- racic Society research statement: nonin- fectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Resp Crit Care Med 2011;183:1262–79. 36. Sano H, Kobayashi R, Iguchi A, et al. Risk factor analysis of idiopathic pneu- monia syndrome after allogeneic hema- topoietic SCT in children. Bone Marrow Transplant 2014;49:38–41. 37. Sakaguchi H, Takahashi Y, Watanabe N, et al. Incidence, clinical features, and risk factors of idiopathic pneumo- nia syndrome following hematopoietic stem cell transplantation in children. Pediatr Blood Cancer 2012;58:780–4. 38. Gower WA, Collaco JM, Mogayzel Jr PJ. Lung function and late pulmonary complications among survivors of he- matopoietic stem cell transplantation 2